Loading
Werewolf Therapeutics, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 14 May 2025.
Werewolf Therapeutics, Inc.: what insiders have been doing
This page follows insider dealings at Werewolf Therapeutics, Inc. as filed with SEC (Form 4), a company from the Healthcare & Pharma sector. Over the twelve months to 18 October 2026, 52 filings were filed, from 8 insiders.
All open-market trades in the period are sales: 40 sales worth €1.6M, by 2 insiders, with no purchase on record. The totals do not cover 3 filings with an undisclosed amount. At €149k, the sale published on 6 November 2025 by MPM BioVentures 2014, L.P. is the largest of the period.
Typically, a trade is published a median of 2 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
Compared with its exchange (5,813 companies, median 19 filings), a count of 52 filings is above the norm. Looking back to 2021, when coverage begins, insiders filed 3 purchases and 41 sales. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists net income at -60.8 m USD.
Other companies in the same sector with recent insider buying flagged by our signals: Cooper Companies, Inc. and Anixa Biosciences Inc. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
83
Thresholds
n/a
Buy Volume
€7M
3 ops. · all time
Sell Volume
€2M
41 ops. · all time
Who traded when
BuySaleLuke Evnin31 sales
Gadicke Ansbert9 sales
MPM BioVentures 2014, L.P.9 sales
RA Capital Management, L.P.1 buy
Since the insiders bought
- -53.6%Entry US$1.11 · Close at T+365 US$0.51
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$0.98
Analyst consensus
3 analysts1.00/5
US$4.00Target US$7.00(+614%)US$10.00
Income statement
EBITDA-US$53.9M
Net income-US$60.8M-164.8% margin
Valuation
PER (forward)-1.7x
P/Book2.9x
Beta0.51
Balance sheet & cash
Market capUS$47.6M
Total debtUS$37.7M
Free Cash Flow-US$60.3M
Debt / Equity309%
Profitability & ownership
ROE-119.9%
ROA-27.4%
% insiders6.6%
% institutions39.2%
Last declaration on 8 July 2026
Declarations83 total
35,770 shares@ US$0.320.024% mcap1.2% of flowCommon StockSEC:0001134657-26-000020:0
107,429 shares@ US$0.310.069% mcap3.4% of flowCommon StockSEC:0001134657-26-000020:1
15,341 shares@ US$0.34040.011% mcap49.0% of flowCommonSEC144:0001628280-26-047365
3,332 shares@ US$0.34040.0023% mcap49.0% of flowCommonSEC144:0001628280-26-047366
6,459 shares@ US$0.34040.0045% mcap49.0% of flowCommonSEC144:0001628280-26-047362
96,873 shares@ US$0.34040.068% mcap3.8% of flowCommonSEC144:0001628280-26-047360
21,194 shares@ US$0.34040.015% mcap49.0% of flowCommonSEC144:0001628280-26-047367
80,142 shares@ US$0.34040.056% mcap49.0% of flowCommonSEC144:0001628280-26-047364
16,830 shares@ US$0.3230.011% mcap51.0% of flowCommonSEC144:0001628280-26-046085
3,657 shares@ US$0.3230.0024% mcap51.0% of flowCommonSEC144:0001628280-26-046086
7,087 shares@ US$0.3230.0047% mcap51.0% of flowCommonSEC144:0001628280-26-046083
106,262 shares@ US$0.3230.071% mcap4.0% of flowCommonSEC144:0001628280-26-046082
23,248 shares@ US$0.3230.016% mcap51.0% of flowCommonSEC144:0001628280-26-046087
87,916 shares@ US$0.3230.059% mcap51.0% of flowCommonSEC144:0001628280-26-046084
157,084 sharesCommon StockSEC:0001134657-26-000019:0
76,928 sharesCommon StockSEC:0001134657-26-000018:0
60,547 sharesCommon StockSEC:0001134657-26-000017:2
20,072 shares@ US$0.440.042% mcap0.9% of flowCommon StockSEC:0001134657-26-000017:0
24,946 shares@ US$0.400.047% mcap1.0% of flowCommon StockSEC:0001134657-26-000017:1
80,852 shares@ US$0.480.15% mcap3.9% of flowCommon StockSEC:0001134657-26-000015:0
27,698 shares@ US$0.460.050% mcap1.3% of flowCommon StockSEC:0001134657-26-000015:1
32,556 shares@ US$0.450.058% mcap1.5% of flowCommon StockSEC:0001134657-26-000015:2
53,940 shares@ US$0.850.27% mcap4.5% of flowCommon StockSEC:0001134657-26-000007:0
95,412 shares@ US$0.730.41% mcap6.9% of flowCommon StockSEC:0001134657-26-000007:1
56,559 shares@ US$0.690.23% mcap3.9% of flowCommon StockSEC:0001134657-26-000007:2
25 of 83 declarations
About Werewolf Therapeutics, Inc.
Werewolf Therapeutics, Inc. (ticker: HOWL) is a U.S.-listed biopharmaceutical company traded on the NASDAQ market in the United States, with headquarters in Watertown, Massachusetts. Founded in 2017 and public since April 2021, the company is focused on a differentiated immuno-oncology strategy built around conditionally activated therapeutics. Its core investment case is straightforward: try to preserve the anti-tumor power of immune-stimulating drugs while reducing the systemic toxicity that has historically limited cytokine-based therapies.
At the center of the story is Werewolf’s proprietary PREDATOR® platform. The platform is designed to create molecules that remain largely inactive in peripheral tissue and become activated preferentially in the tumor microenvironment. That approach underpins the company’s INDUKINE™ programs, which aim to unleash immune activity where it is most needed while limiting off-tumor exposure. Werewolf’s two lead clinical-stage candidates are WTX-124, a conditionally activated IL-2 INDUKINE molecule, and WTX-330, a conditionally activated IL-12 INDUKINE molecule. Both are being developed primarily for solid tumors, where the company is seeking to demonstrate a better balance of efficacy and tolerability than conventional pro-inflammatory immunotherapies.
Read moreShow less
Beyond cytokines, Werewolf has also highlighted its INDUCER™ T-cell engager platform, which broadens the technology base and potentially expands its pipeline optionality. Competitive positioning is meaningful but challenging: the company operates in a crowded field of oncology biotech innovators and large pharmaceutical groups pursuing next-generation immunotherapies, bispecifics, and cell-engaging approaches. Werewolf’s differentiation lies in its masking/activation chemistry and the ambition to tune immune stimulation more precisely than traditional cytokine platforms. At the same time, the company remains a development-stage biotech, so valuation is highly sensitive to clinical readouts, regulatory progress, and financing conditions.
Recent corporate updates have been especially important. In 2025 and 2026, Werewolf reported pipeline progress across WTX-124 and WTX-330, including additional clinical updates and a renewed emphasis on the INDUCER platform and partnership opportunities. In March 2026, management disclosed that it was exploring strategic alternatives to maximize shareholder value, including a possible sale, merger, asset transaction, licensing deal, or collaboration. The company’s first-quarter 2026 filing also showed a major restructuring, including a 64% workforce reduction, underscoring the effort to conserve capital and align resources with the strategic review. For investors, HOWL is therefore best viewed as an innovative but high-risk clinical-stage biotechnology name, with value creation tied to clinical validation and potential strategic optionality.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
